In soft tissue sarcoma, pazopanib improves PFS without affecting HRQoL
the ONA take:
Pazopanib improved progression-free survival but did not impact health-related quality of life in patients with soft tissue sarcoma who experienced disease progression during or after prior chemotherapy, according to a new study published in the journal Cancer.
The global, double-blind, phase III PALETTE trial found that pazopanib 800 mg as second-line or later treatment improved median progression-free survival by 3 months compared with placebo in patients with advanced soft tissue sarcoma. Researchers also found that the most common adverse events associated with pazopanib treatment were diarrhea, fatigue, hypertension, nausea, and weight loss.
Researchers also conducted an exploratory analysis to evaluate the impact of pazopanib treatment on health-related quality of life. Patients were assessed using the 30-item core EORTC Quality-of-Life Questionnaire at baseline and at 4, 8, and 12 weeks of treatment.
Results showed that there was no statistically significant different in global health status between pazopanib and placebo; however, those receiving pazopanib reported significantly worse scores for diarrhea, fatigue, loss of appetite, and nausea/vomiting than those who received placebo. Researchers found that health-related quality of life score tended to decrease over time in both treatment groups.
Pazopanib (Votrient) was initially approved by the U.S. Food and Drug Administration in 2009 for the treatment of patients with advanced renal cell carcinoma.
Pazopanib improved PFS but did not impact HRQoL in patients with soft tissue sarcoma who experienced disease progression during or after prior chemo.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|